Aviceda is an innovative clinical-stage biotech company focused on the next generation of glyco-immune therapeutics for patients with immune system dysfunction.
Cambridge, MA
Joined January 2020
- Tweets140
- Following34
- Followers92
- Likes19
Catch this profile of Aviceda Therapeutics Co-Founder Michael J. Tolentino, MD, in @USAToday. #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula
usatoday.com/story/special/c…
215
Sun, fun, and teamwork! 📷 The Aviceda Team had an incredible day bonding over a scavenger hunt, kayaking along the Charles River, and enjoying dinner at the Glass House in Cambridge. These experiences strengthen our team spirit and creativity and recharge our batteries.
157
Rishi Singh, MD, reviews findings from the Phase 2a SIGLEC study assessing the safety and efficacy of AVD-104 for geographic atrophy secondary to AMD at this year’s #ASRS2024 meeting in Stockholm #glycoimmunology #biotech #innovation #ophthalmology #retina
ophthalmologytimes.com/view/…
115
At ASRS on Thursday, July 18, at 1:24 pm, Rishi Singh, MD, will share safety and efficacy results from the Phase 2a SIGLEC trial assessing AVD-104 for geographic atrophy secondary to AMD. #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula
1
144
At ASRS on Thursday, July 18, at 1:28 pm, David Boyer, MD, will explore anatomic changes in GA patients who received a single injection of AVD-104 in the phase 2a SIGLEC study. #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula
101
Aviceda wishes everyone a Happy Fourth of July! Enjoy the day with your family and friends—and be sure to rest up for a busy summer ahead.
#retina
#glycoimmunology
#biotech
#innovation
#ophthalmology
#GA
#AMD
#macula
78
Join us on Saturday June 8, at 10:27am as David Callanan, MD, sits on a panel moderated by Jeffrey Heier, MD. They will explore the state of play in geographic atrophy and explore what the next generation of therapies could (and should) look like #glycoimmunology #ophthalmology
55
Join us on Saturday, June 8, at 10:07am for Clinical Trials at the Summit as Tarek Hassan, MD, takes the stage to explore how a new approach to treating geographic atrophy could lead to a paradigm shift in disease treatment #glycoimmunology #ophthalmology #retina #GA #AMD #macula
86
At Clinical Trials at the Summit on Saturday, June 8, at 10:11am, Arshad Khanani, MD, MA, will explore the findings of the SIGLEC Phase 2a study. #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula
76
Don’t miss the late-breaker session on Sunday, May 12, at Retina World Congress. Robert Avery, will present the latest data from Part 1 of the Phase 2/3 SIGLEC study assessing AVD-104 for the treatment of geographic atrophy secondary to AMD. #geographicatrophoy #retina
70
David Callanan, MD Chief Medical Officer at Aviceda Therapeutics, will be part of the RWC Unplugged Panel on Thurs, 5/9, discussing geographic atrophy at this year’s Retina World Congress. Join him to hear his insights about the future of #geographicatrophy treatments in #retina
55
Congratulations to Kinkini Roy, PhD, for leading an excellent presentation titled “Surface-modified LNP: Stability & Characterization” at this year’s LNP Formulation and Process Development Summit in Boston! Once again, the Aviceda team helps lead the conversation on innovation.
46
Work from the Aviceda Therapeutics team has been published once again in the journal Pharmaceuticals. Read it here: mdpi.com/1424-8247/17/4/517 #glycoimmunology #biotech #innovation #ophthalmology #retina
1
52
The team at Aviceda Therapeutics is proud to announce the publication of a new manuscript in the journal Pharmaceuticals. You can read the journal entry here: mdpi.com/1424-8247/17/4/481 #glycoimmunology #biotech #innovation #ophthalmology #retina
1
66
Aviceda Therapeutics Announces Formation of Renowned European Clinical Advisory Board businesswire.com/news/home/2… #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula
1
89
Don’t miss Chief Development Officer Tarek Hassan, MD, as he accepts his Lifetime Achievement Award from the Vit-Buckle Society at #VBS2024! Dr. Hassan will take the stage at 11:10am ET to deliver his lecture “Nobody Normal Ever Accomplished Anything.”
1
50
On April 10, the Aviceda Executive Team will participate in the 23rd Annual Needham Virtual Healthcare Conference. Our Chief Medical Officer David Callanan, MD, will present an update on AVD-104 and the SIGLEC GA trial, covering #glycoimmunology in #ophthalmology and beyond.
1
62
In the most recent issue of CXO Outlook, Aviceda’s CEO and Co-founder Mohamed Genead, MD, was profiled as the Most Inspiring Business Leader for 2024. Read more: cxooutlook.com/building-on-a… #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula
73
This week, Aviceda Therapeutics participated in a virtual fireside chat with Truist about the dynamics in the marketplace for geographic atrophy. Watch the interview here: openexc.zoom.us/webinar/regi… #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula
72
Join Tarek Hassan, MD, at the #BRAVS2024 meeting in Campinas, Brazil, as he discusses how glyco-immune macrophage modulation could be key to unlocking the next era of geographic atrophy treatment. #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula
1
111